NCT04865458

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies

A Phase I Single Arm,Open-label,Multiple Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Sunshine Lake Pharma Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the safety, pharmacokinetics and efficacy of HEC89736 in patients with Relapsed or Refractory B-cell Hematologic Malignancies

Conditions

• Relapsed or Refractory B-cell Hematologic Malignancies

Interventions

Type	Name	Description
DRUG	HEC89736	HEC89736 tablets QD every 28 days for each cycle

Timeline

• Start date: 2021-04-01
• Primary completion: 2023-04-01
• Completion: 2024-04-01
• First posted: 2021-04-29
• Last updated: 2022-05-06

Locations

2 sites across 1 country: China